SEC Form 4 · accession 0001615219-15-000025
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christoph H Westphal
Officer — President and CEO · Director · 10% Owner
Period of report
Jul 6, 2015
Accepted (ET)
Jul 8, 2015 · 8:38 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001615219
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2015 | P | 342 | $16.1988 | A | 3,907,003 | D | |
| Common StockF2 | holding | — | — | — | 2,697,264 | I | By Longwood Fund II. L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2015.
- F2Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund II, L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.